<DOC>
	<DOCNO>NCT00003060</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Clinical trial study effectiveness chemotherapy plus bone marrow transplantation treat patient metastatic melanoma respond previous therapy .</brief_summary>
	<brief_title>Chemotherapy Plus Bone Marrow Transplantation Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate survival patient metastatic malignant melanoma fail first-line therapy treat match-related allogeneic bone marrow transplantation . OUTLINE : This pilot study . Patients receive preparative regimen busulfan cyclophosphamide . Busulfan PO administer every 6 hour day -7 -4 . Cyclophosphamide IV administer day -3 -2 follow one day rest . Bone marrow infusion occur day 0 . Cyclosporine begin day -1 continue day 180 . Methotrexate IV administer day 1 , 3 , 6 , 11 . Granulocyte colony-stimulating factor administer continuous IV every 2 hour start day 12 continue absolute neutrophil count great 1,000 g/dL 2 consecutive day . Patients receive weekly follow first 180 day monthly thereafter . Patients follow death . PROJECTED ACCRUAL : 6 patient melanoma accrue .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy proven relapse malignant melanoma fail prior standard regimen metastatic disease Must HLAmatched relate bone marrow donor ( 5 6antigen match ) No history CNS metastases PATIENT CHARACTERISTICS : Age : 16 44 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : SGOT SGPT less 1.5 time upper limit normal Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL AND/OR Creatinine clearance great 75 mL/min Cardiovascular : No history cardiac disease No symptomatic cardiac disease Ejection fraction great 50 % Pulmonary : FEV1 great 50 % predict ( great 75 % receive thoracic irradiation ) DLCO great 50 % predict Other : Not pregnant Fertile woman must use effective contraception HIV negative No active bacterial , fungal , viral infection Hepatitis B negative PRIOR CONCURRENT THERAPY : At least 1 prior standard regimen metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>recurrent melanoma</keyword>
</DOC>